Since our start in 2016, End­points News has grown fast while ex­e­cut­ing our mis­sion to cov­er bio­phar­ma’s most crit­i­cal de­vel­op­ments for in­dus­try pros world­wide. As read­er­ship has grown, our ad­ver­tis­ing busi­ness has too. End­points ad­ver­tis­ing part­ners sup­port the mis­sion and en­gage their de­sired au­di­ences through an­nounce­ments on our email and web plat­forms, brand recog­ni­tion in our event cov­er­age and spon­sor­ships of End­points dai­ly and week­ly re­ports.

And to­day, we’re launch­ing our newest evo­lu­tion of the busi­ness: End­points Stu­dio.

Now, life sci­ences mar­keters can pro­duce brand­ed con­tent in the cal­iber read­ers ex­pect from End­points. Led by Kari Abit­bol, our new head of ad­ver­tis­ing and mar­ket­ing pro­grams, the End­points Stu­dio team de­vel­ops mea­sur­able cam­paigns in­formed with our first-par­ty da­ta.

Our line­up fea­tures the Stu­dio FSP and Stu­dio FSP+, an en­hance­ment of our long-es­tab­lished spon­sored posts with ar­ti­cles au­thored by our Stu­dio team — with an op­por­tu­ni­ty to do lead-cap­ture. Stu­dio FSP and FSP+ ben­e­fit from the same, ex­clu­sive pro­mo­tion across our email re­ports, home­page and news streams. We’re al­so in­tro­duc­ing Stu­dio we­bi­na­rs, which run like cus­tom and ed­i­to­r­i­al we­bi­na­rs but are pro­grammed ex­clu­sive­ly by our Stu­dio team, and E-blast+, which in­cludes an End­points-cre­at­ed and host­ed land­ing page de­signed for high con­ver­sion.

So what makes End­points Stu­dio dif­fer­ent, ex­act­ly? Check out the new stu­dio web­site to learn more about our prod­ucts, top­ics (which span cell and gene ther­a­py to phar­ma mar­ket­ing) and how we use our own da­ta to de­liv­er bet­ter con­tent for our read­ers and stronger re­sults for our ad­ver­tis­ers. And soon, you’ll see case stud­ies about how we’re learn­ing from our own Stu­dio pro­grams to gen­er­ate even greater im­pact.

In 2021, our com­mit­ment was to go broad­er and deep­er. We launched four week­ly re­ports — End­points Man­u­fac­tur­ing, End­points Week­ly, End­points FDA+ and the new­ly re­leased End­points Mar­ket­ingRx — and de­liv­ered break­ing news that fu­eled a wave of new sub­scribers. Our ac­tive email dai­ly read­er­ship is near­ing 125,000 sub­scribers as we close out the year. We’ve grown our team from 22 full-time staff in Jan­u­ary to 35 full-time em­ploy­ees (and count­ing) to ma­ture and sup­port these ini­tia­tives at scale.

As we look to the year ahead, we’re great­ly thank­ful for the con­tin­ued sup­port from read­ers, sub­scribers and spon­sors that has cat­a­pult­ed us from a small me­dia com­pa­ny in­to a thriv­ing force whose work is seen dai­ly by lead­er­ship at the top 25 phar­ma com­pa­nies and thou­sands of biotech star­tups across the globe. And we’re just get­ting start­ed.

Stay tuned for more End­points Stu­dio up­dates from Kari next year. For Stu­dio sched­ul­ing and pric­ing re­quests, con­tact our Stu­dio sales team here.

The FDA’s Oncology Center of Excellence has been a bright spot within the agency in terms of speeding new treatments to patients. That flexibility was on full display this morning as FDA released new draft guidance spelling out exactly how oncology drug developers can fulfill both the accelerated and full approval’s requirements with just a single randomized controlled trial.

While Congress recently passed legislation that will allow FDA to require confirmatory trials to be recruiting and ongoing prior to granting an accelerated approval, the agency is now making clear that the initial trial used to win the AA, if designed appropriately, can also serve as the trial for converting the accelerated approval into a full approval.

US regulators cleared an ultra-rare drug from Pharming Group, by way of Novartis, on Friday afternoon.

The Dutch biotech said the FDA greenlit leniolisib for an immunodeficiency disease known as activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome, or APDS. People 12 years and older can receive the oral drug, to be marketed as Joenja, beginning early next month, Pharming said, five days ahead of the decision deadline set by the FDA as part of a priority review.

A California judge will allow a plaintiff in a state court case to introduce expert testimony connecting a potential carcinogen in former blockbuster medicine Zantac to cancer.

The order was handed down on Thursday from state judge Evelio Grillo, who is now allowing both parties to introduce expert testimony in an upcoming trial after what’s known as a Sargon hearing, where a judge determines the admissibility of expert witnesses and expert opinions.